Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study.

PLoS neglected tropical diseases - 1 Mar 2026

Corder Rodrigo M, Puça Maria Carolina S B, Prete Carlos A, Ladeia Winni A, Rodrigues Priscila T, Johansen Igor C, de Sousa Tais Nobrega, Ferreira Marcelo U

Abstract excerpt

BACKGROUND: Primaquine (PQ) is the only widely available drug that eliminates latent hypnozoites, thereby preventing relapses of Plasmodium vivax malaria. Because PQ biotransformation mediated by the cytochrome P-450 (CYP) isoenzyme CYP2D6 is required for therapeutic activity, patients with reduced CYP2D6 activity can experience relapse despite treatment. The minimum level of CYP2D6 activity for adequate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimalarials
Share to Brazil

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chloroquine

Share to Cohort Studies

Share to Cytochrome P-450 CYP2D6

Share to Malaria, Vivax

Share to Plasmodium vivax

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 41894411
DOI: 10.1371/journal.pntd.0014160
PMCID: PMC13048497

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study.PMID 41894411Read ↗

Differential impact of Tafenoquine and Primaquine on Plasmodium vivax recurrence: the role of CYP2D6 variants.Semantic proximity Read ↗

Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.Semantic proximity Read ↗

Efficacy of Primaquine for the Radical Cure of Plasmodium vivax Malaria in Northeast Myanmar and the Impact of Cytochrome P450 2D6 Genotypes.Semantic proximity Read ↗

CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.Semantic proximity Read ↗

Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for LatentPlasmodium vivaxMalariaSemantic proximity Read ↗

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trialSemantic proximity Read ↗

Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis.Semantic proximity Read ↗

Impact of CYP2D6, MAOA, and UGT2B7 genetic variants on recurrence of Plasmodium Vivax in the Brazilian AmazonSemantic proximity Read ↗

Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.Semantic proximity Read ↗

Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients.Semantic proximity Read ↗

Genetic Polymorphism of Cyp2d6 Gene Coding Region and Association Between Them With Vivax Malaria Relapse in Yunnan Province, ChinaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.